Intrinsic ubiquitination activity of PCAF controls the stability of the oncoprotein Hdm2

Nature Cell Biology

Volumn 9, Issue 3, 2007, Pages 331-338

  Linares, Laëtitia K ^a   Kiernan, Rosemary ^b   Triboulet, Robinson ^b   Chable Bessia, Christine ^b   Latreille, Daniel ^b   Cuvier, Olivier ^b   Lacroix, Matthieu ^c   Le Cam, Laurent ^c   Coux, Olivier ^a   Benkirane, Monsef ^b  

^a Centre National de la Recherche Scientifique   (France)

^b INSTITUTE OF HUMAN GENETICS   (France)

^c CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE ACETYLTRANSFERASE PCAF; ONCOPROTEIN; PROTEIN MDM2; PROTEIN P53; UBIQUITIN PROTEIN LIGASE E3;

ARTICLE; CONTROLLED STUDY; DNA DAMAGE; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME REGULATION; GENOTOXICITY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; TRANSCRIPTION REGULATION; UBIQUITINATION;

APOPTOSIS; BINDING SITES; CATALYTIC DOMAIN; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA DAMAGE; GENE EXPRESSION; HELA CELLS; HISTONE ACETYLTRANSFERASES; HUMANS; MUTATION; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MDM2; RNA, ANTISENSE; RNA, SMALL INTERFERING; TRANSCRIPTION FACTORS; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN; UBIQUITIN-PROTEIN LIGASES; ULTRAVIOLET RAYS; ZINOSTATIN;

EID: 33847388041     PISSN: 14657392     EISSN: None     Source Type: Journal    
DOI: 10.1038/ncb1545     Document Type: Article

References (31)

1. Schiltz, R. L. & Nakatani, Y. The PCAF acetylase complex as a potential tumor suppressor. Biochim. Biophys. Acta 1470, M37-M53 (2000).
2. Vargas, D. A., Takahashi, S. & Ronai, Z. Mdm2: A regulator of cell growth and death. Adv. Cancer Res. 89, 1-34 (2003).
3. Iwakuma, T. & Lozano, G. MDM2, an introduction. Mol. Cancer Res. 1, 993-1000 (2003).
4. Bond, G. L., Hu, W. & Levine, A. J. MDM2 is a central node in the p53 pathway: 12 years and counting. Curr. Cancer Drug Targets 5, 3-8 (2005).
5. Liu, L. et al. p53 sites acetylated in vitro by PCAF and p300 are acetylated in vivo in response to DNA damage. Mol. Cell. Biol. 19, 1202-1209 (1999).
6. Fang, S., Jensen, J. P., Ludwig, R. L., Vousden, K. H. & Weissman, A. M. Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J. Biol. Chem. 275, 8945-8951 (2000).
7. Linares, L. K., Hengstermann, A., Ciechanover, A., Muller, S. & Scheffner, M. HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53. Proc. Natl Acad. Sci. USA 100, 12009-12014 (2003).
8. Hershko, A., Ciechanover, A. & Varshavsky, A. The ubiquitin system. Nature Med. 6, 1073-1081 (2000).
9. Stommel, J. M. & Wahl, G. M. A new twist in the feedback loop: stress-activated MDM2 destabilization is required for p53 activation. Cell Cycle 4, 411-417 (2005).
10. Lorick, K. L. et al. RING fingers mediate ubiquitin-conjugating enzyme (E2)-dependent ubiquitination. Proc. Natl Acad. Sci. USA 96, 11364-11369 (1999).
11. Caron, C., Boyault, C. & Khochbin, S. Regulatory cross-talk between lysine acetylation and ubiquitination: Role in the control of protein stability. Bioessays 27, 408-415 (2005).
12. Grossman, S. R. et al. Polyubiquitination of p53 by a ubiquitin ligase activity of p300. Science 300, 342-344 (2003).
13. Wertz, I. E. et al. De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-κB signalling. Nature 430, 694-699 (2004).
14. Robinson, P. A. & Ardley, H. C. Ubiquitin-protein ligases. J. Cell Sci. 117, 5191-5194 (2004).
15. Stommel, J. M. & Wahl, G. M. Accelerated MDM2 auto-degradation induced by DNA-damage kinases is required for p53 activation. EMBO J. 23, 1547-1556 (2004).
16. Kroll, M. et al. Inducible degradation of IκBα by the proteasome requires interaction with the F-box protein h-βTrCP. J. Biol. Chem. 274, 7941-7945 (1999).
17. Wang, X., Taplick, J., Geva, N. & Oren, M. Inhibition of p53 degradation by Mdm2 acetylation. FEBS Lett. 561, 195-201 (2004).
18. Vogelstein, B., Lane, D. & Levine, A. J. Surfing the p53 network. Nature 408, 307-310 (2000).
19. Michael, D. & Oren, M. The p53-Mdm2 module and the ubiquitin system. Semin. Cancer Biol. 13, 49-58 (2003).
20. Lakin, N. D. & Jackson, S. P. Regulation of p53 in response to DNA damage. Oncogene 18, 7644-7655 (1999).
21. Hengstermann, A., Linares, L. K., Ciechanover, A., Whitaker, N. J. & Scheffner, M. Complete switch from Mdm2 to human papillomavirus E6-mediated degradation of p53 in cervical cancer cells. Proc. Natl Acad. Sci, USA 98, 1218-1223 (2001).
22. Barlev, N. A. et al. Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases. Mol. Cell 8, 1243-1254 (2001).
23. You, H., Yamamoto, K. & Mak, T. W. Regulation of transactivation-independent proapoptotic activity of p53 by FOXO3a. Proc. Natl Acad. Sci. USA 103, 9051-9056 (2006).
24. Brooks, C. L. & Gu, W. p53 Ubiquitination: Mdm2 and beyond. Mol. Cell 21, 307-315 (2006).
25. Jin, Y., Zeng, S. X., Lee, H. & Lu, H. MDM2 mediates p300/CREB-binding protein-associated factor ubiquitination and degradation. J. Biol. Chem. 279, 20035-20043 (2004).
26. Jin, Y., Zeng, S. X., Dai, M. S., Yang, X. J. & Lu, H. MDM2 inhibits PCAF (p300/CREB-binding protein-associated factor)-mediated p53 acetylation. J. Biol. Chem. 277, 30838-30843 (2002).
27. Bode, A. M. & Dong, Z. Post-translational modification of p53 in tumorigenesis. Nature Rev. Cancer 4, 793-805 (2004).
28. Vousden, K. H. & Prives, C. p53 and prognosis: New insights and further complexity. Cell 120, 7-10 (2005).
29. Bres, V. et al. Differential acetylation of Tat coordinates its interaction with the coactivators cyclin T1 and PCAF. EMBO J. 21, 6811-6819 (2002).
30. Sun, X. Z., Nguyen, J. & Momand, J. Purification of recombinant p53 from Sf9 insect cells. Methods Mol. Biol. 234, 17-28 (2003).
31. Cuvier, O., Hart, C. M., Kas, E. & Laemmli, U. K. Identification of a multicopy chromatin boundary element at the borders of silenced chromosomal domains. Chromosoma 110, 519-531 (2002).